Financing Cash Flow
Vertex Pharmaceuticals Financing Cash Flow decreased by 597.9% to -$538.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.8%, from -$680.40M to -$538.80M. Over 3 years (FY 2021 to FY 2025), Financing Cash Flow shows a downward trend with a 15.2% CAGR.
Analysis
How to read this metric
A large negative value typically indicates a company is returning capital to shareholders or paying down debt, while a positive value suggests the company is raising external capital to fund operations or acquisitions.
Detailed definition
This metric represents the net flow of cash between a company and its capital providers, including shareholders and lend...
Peer comparison
Large-cap peers like Microsoft or Alphabet similarly show large negative financing outflows due to aggressive share repurchase programs and dividend distributions.
net_cash_from_financingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $33.55M | -$656.66M | -$336.24M | -$95.40M | $47.70M | -$60.20M | -$294.70M | $17.30M | -$165.00M | -$119.80M | -$357.50M | -$358.60M | -$387.50M | -$391.30M | -$680.40M | -$349.20M | -$1.15B | -$77.20M | -$538.80M |
| QoQ Change | — | <-999% | +48.8% | +71.6% | +150.0% | -226.2% | -389.5% | +105.9% | <-999% | +27.4% | -198.4% | -0.3% | -8.1% | -1.0% | -73.9% | +48.7% | -230.6% | +93.3% | -597.9% |
| YoY Change | — | — | — | — | +42.2% | +90.8% | -208.9% | -63.7% | -174.1% | — | -21.3% | <-999% | -134.8% | -226.6% | -90.3% | +2.6% | -197.9% | +80.3% | +20.8% |
Financing Cash Flow at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's financing cash flow?
- Vertex Pharmaceuticals (VRTX) reported financing cash flow of -$538.80M in Q1 2026.
- How has Vertex Pharmaceuticals's financing cash flow changed year-over-year?
- Vertex Pharmaceuticals's financing cash flow increased by 20.8% year-over-year, from -$680.40M to -$538.80M.
- What is the long-term trend for Vertex Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's financing cash flow has grown at a 15.2% compound annual growth rate (CAGR), from -$1.48B to -$2.26B.
- What does financing cash flow mean?
- The total amount of money a company spends or receives from borrowing debt and managing its own shares and dividends.